Pyrotinib maleate
Pre-clinicalUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2 Mutant Non-small Cell Lung Cancer
Conditions
HER2 Mutant Non-small Cell Lung Cancer
Trial Timeline
Jun 30, 2022 → Dec 31, 2024
NCT ID
NCT05411276About Pyrotinib maleate
Pyrotinib maleate is a pre-clinical stage product being developed by Jiangsu Hengrui Medicine for HER2 Mutant Non-small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05411276. Target conditions include HER2 Mutant Non-small Cell Lung Cancer.
What happened to similar drugs?
2 of 20 similar drugs in HER2 Mutant Non-small Cell Lung Cancer were approved
Approved (2) Terminated (1) Active (17)
Hype Score Breakdown
Clinical
3
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05411276 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in HER2 Mutant Non-small Cell Lung Cancer